Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Dr Lihua Zheng China

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
Website:
http://anhearttherapeutics.com/en/home/
Company Size (Fulltime employees)
11-50
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
1/Funding Raising for Series B; 2/Pipeline Asset EU and Korea out licensing; 3/In licensing new clinical PoC oncology assets
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
Taletrectinib|next-gen ROS1/NTRK inhibitor, the leading program, currently in a Phase 2 trial in China and ex-China global trials to start in early 2021|ROS1+ NSCLC|Global
Assets Information 2
AB-218/DS-1001|a potentially best-in-class mIDH-1 inhibitor in co-development with Daiichi Sankyo (Japan rights), to start with ex-Japan global Phase 2 trials in glioma and conduct preclinical and clinical POC studies in other indications|IDH1+ Lower Grade Glioma|ex-Japan
Assets Information 3
AB-329/DS-1205|a potentially best-in-class AXL inhibitor, to start with preclinical and clinical POC studies in multiple indications|combo with PD-1 ab for NSCLC|Global
Biotech/Pharma Asset Stage
Dr Lihua Zheng
AnHeart Therapeutics
LinkedIn logo CBO & co-Founder 
Functionality
Management

Linda Zheng China

A French PHARMA & cosmetics company
Website:
www.Pierre-Fabre.com
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Pierre Fabre Medicament China
Senior Market Access & Health Economics Director 

Jia Zhilong China

a large hospital
Website:
www.301hospital.com.cn
Partnering Objectives
Headquartner in China
Yes
Chinese PLA general hospital
assistant professor 

Sandra Zhong China

Partnering Objectives
Suzhou Kintor Pharmaceuticals, Inc.
BD Director 

Bella Zhou China

戴德梁行 国际五大行之一
Website:
Cushman.com
Partnering Objectives
Headquartner in China
No
Cushman
Associate director 

yanfei zhou China

ZhongXi Capital focus on biomedical investment，fiancing，consulting and other capital market business.
Website:
无
Partnering Objectives
Headquartner in China
Yes
ZhongXi Capital
高级投资经理 

Min Zhou China

Hainan Haiyao, a Chinese public company with stock code of 000566, is established in 1965, mainly focused on some severe diseases such as infection, tumor, digestion system etc.
Website:
www.haiyao.com.cn
Partnering Objectives
Headquartner in China
Yes
Hainan Haiyao Co. , Ltd
BD Director 

ping zhou China

略
Website:
www.jitri.org
Partnering Objectives
Headquartner in China
Yes
江苏省产业技术研究院
senior business manager 

Monica Zhou China

Established in Shenzhen Special Economic Zone in 1992;
Core competitiveness - A specialty company in digestion and intestinal microecology and a national level Hi-tech Enterprise.
Website:
www.wanhe-phar.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Shenzhen Wanhe Pharma
BD 

James Zhou China

A biotech company headquartered in China with clinically validated integrated platform for drug discovery and development.  We focus on oncology and inflammatory disease. There are four projects on Phase I clinical stage.

Website:
http://www.transtherabio.com/
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Nanjing TransTherabio
Director